Inhibition of glycosphingolipid synthesis ameliorates atherosclerosis and arterial stiffness in apolipoprotein E-/-Mice and rabbits fed a high-fat and -cholesterol diet

Circulation

Volumn 129, Issue 23, 2014, Pages 2403-2413

  Chatterjee, Subroto ^a   Bedja, Djahida ^b,d,e   Mishra, Sumita ^a   Amuzie, Christine ^a   Avolio, Alberto ^d,e   Kass, David A ^b   Berkowitz, Dan ^c   Renehan, Mark ^a  

^a Departments of Pediatrics   (United States)

^b Boston University Medical Center Place   (United States)

^c Departments of Anesthesiology and Critical Care Medicine   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e MACQUARIE UNIVERSITY   (Australia)

Author keywords

Atherosclerosis; Glycosphingolipids; Knockout; Mice; Molecular imaging

Indexed keywords

ABC TRANSPORTER G5; ABC TRANSPORTER G8; ANTILIPEMIC AGENT; APOLIPOPROTEIN E; CALCIUM; CERAMIDE DERIVATIVE; CERAMIDE GLUCOSYLTRANSFERASE; CHOLESTEROL; DEXTRO THREO 1 PHENYL 2 DECANOYLAMINO 3 MORPHOLINO 1 PROPANOL; GLUCOSYLCERAMIDE; GLYCOSPHINGOLIPID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LACTOSYLCERAMIDE; LACTOSYLCERAMIDE SYNTHASE; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN RECEPTOR; OXIDIZED LOW DENSITY LIPOPROTEIN; POLYSORBATE 80; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA INTIMA; ARTERIAL STIFFNESS; ARTERIAL WALL THICKENING; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; BILE ACID SYNTHESIS; BODY WEIGHT; BONE DENSITY; BONE MASS; CATABOLISM; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CHOLESTEROL METABOLISM; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ENZYME ACTIVITY; EXPERIMENTAL RABBIT; GENE EXPRESSION; HYPERLIPIDEMIA; LIPID DIET; LIPOGENESIS; MALE; MOUSE; MUSCLE MASS; NONHUMAN; PRIORITY JOURNAL; PULSE WAVE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TRIACYLGLYCEROL BLOOD LEVEL;

ATHEROSCLEROSIS; GLYCOSPHINGOLIPIDS; MICE, KNOCKOUT; MOLECULAR IMAGING;

ANIMALS; ANTIGENS, CD; AORTA; APOLIPOPROTEINS E; CALCIUM; CHOLESTEROL, DIETARY; CORONARY ARTERY DISEASE; DIET, HIGH-FAT; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; GENE EXPRESSION REGULATION; GLUCOSYLCERAMIDES; GLYCOSPHINGOLIPIDS; HYPERLIPIDEMIAS; LACTOSYLCERAMIDES; LIPOPROTEINS, LDL; MALE; MICE; MICE, KNOCKOUT; MODELS, CARDIOVASCULAR; MORPHOLINES; PULSATILE FLOW; RABBITS; VASCULAR STIFFNESS;

EID: 84902172850     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.113.007559     Document Type: Article

References (29)

1. Chatterjee, S. Pathophysiology and Vascular Biology in Atherosclerosis. In: The Johns Hopkins Textbook of Dyslipidemia, 1st ed. Baltimore, MD: Lippincott, Williams & Wilkins; 2010: 48-57.
2. Dawson G, Kruski AW, Scanu AM. Distribution of glycosphingolipids in the serum lipoproteins of normal human subjects and patients with hypoand hyperlipidemias. J Lipid Res. 1976;17:125-131.
3. Chatterjee S, Kwiterovich PO. Glycosphingolipids of human plasma lipoproteins. Lipids. 1976;11:462-466.
4. Bhunia AK, Arai T, Bulkley G, Chatterjee S. Lactosylceramide mediates tumor necrosis factor-alpha-induced intercellular adhesion molecule-1 (ICAM-1) expression and the adhesion of neutrophil in human umbilical vein endothelial cells. J Biol Chem. 1998;273:34349-34357. (Pubitemid 29008913)
5. Gong N, Wei H, Chowdhury SH, Chatterjee S. Lactosylceramide recruits PKCα/ε and phospholipase A2 to stimulate PECAM-1 expression in human monocytes and adhesion to endothelial cells. Proc Natl Acad Sci U S A. 2004;101:6490-6495. (Pubitemid 38586001)
6. Glaros EN, Kim WS, Quinn CM, Wong J, Gelissen I, Jessup W, Garner B. Glycosphingolipid accumulation inhibits cholesterol efflux via the ABCA1/apolipoprotein A-I pathway: 1-phenyl-2-decanoylamino-3-morpholino- 1-propanol is a novel cholesterol efflux accelerator. J Biol Chem. 2005;280:24515-24523. (Pubitemid 40934537)
7. Chatterjee S, Ghosh N. Oxidized low density lipoprotein stimulates aortic smooth muscle cell proliferation. Glycobiology. 1996;6:303-311. (Pubitemid 26156450)
8. Bietrix F, Lombardo E, van Roomen CP, Ottenhoff R, Vos M, Rensen PC, Verhoeven AJ, Aerts JM, Groen AK. Inhibition of glycosphingolipid synthesis induces a profound reduction of plasma cholesterol and inhibits atherosclerosis development in APOE*3 Leiden and low-density lipoprotein receptor-/-mice. Arterioscler Thromb Vasc Biol. 2010;30:931-937.
9. Kamani M, Mylvaganam M, Tian R, Rigat B, Binnington B, Lingwood C. Adamantyl glycosphingolipids provide a new approach to the selective regulation of cellular glycosphingolipid metabolism. J Biol Chem. 2011;286:21413-21426.
10. Radin NS, Shayman JA, Inokuchi J. Metabolic effects of inhibiting glucosylceramide synthesis with PDMP and other substances. Adv Lipid Res. 1993;26:183-213.
11. Chatterjee S. Assay of lactosylceramide synthase and comments on its potential role in signal transduction. Methods Enzymol. 2000;311:73-81.
12. Basu M, De T, Das KK, Kyle JW, Chon HC, Schaeper RJ, Basu S. Glycolipids. Methods Enzymol. 1987;138:575-607.
13. Habashi JP, Holm TM, Doyle JJ, Aziz H, Bedja D, Dietz HC. At2 signaling is a positive prognostic and therapeutic modifier of Marfan syndrome: lessons on the inequality of ACEI and ARBs. Circulation. 2009;120:S963-S963.
14. Olson LE, Bedja D, Alvey SJ, Cardounel AJ, Gabrielson KL, Reeves RH. Protection from doxorubicin-induced cardiac toxicity in mice with a null allele of carbonyl reductase 1. Cancer Res. 2003;63:6602-6606. (Pubitemid 37336434)
15. Jun J, Reinke C, Bedja D, Berkowitz D, Bevans-Fonti S, Li J, Barouch LA, Gabrielson K, Polotsky VY. Effect of intermittent hypoxia on atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis. 2010;209:381-386.
16. Sussan TE, Jun J, Thimmulappa R, Bedja D, Antero M, Gabrielson KL, Polotsky VY, Biswal S. Disruption of Nrf2, a key inducer of antioxidant defenses, attenuates ApoE-mediated atherosclerosis in mice. PLoS One. 2008;3:e3791.
17. Sussan TE, Rangasamy T, Blake DJ, Malhotra D, El-Haddad H, Bedja D, Yates MS, Kombairaju P, Yamamoto M, Liby KT, Sporn MB, Gabrielson KL, Champion HC, Tuder RM, Kensler TW, Biswal S. Targeting Nrf2 with the triterpenoid CDDO-imidazolide attenuates cigarette smokeinduced emphysema and cardiac dysfunction in mice. Proc Natl Acad Sci U S A. 2009;106:250-255.
18. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959;37:911-917.
19. Zama K, Hayashi Y, Ito S, Hirabayashi Y, Inoue T, Ohno K, Okino N, Ito M. Simultaneous quantification of glucosylceramide and galactosylceramideby normal-phase HPLC using O-phtalaldehyde derivatives prepared with sphingolipid ceramide N-deacylase. Glycobiology. 2009;19:767-775.
20. Garner B, Priestman DA, Stocker R, Harvey DJ, Butters TD, Platt FM. Increased glycosphingolipid levels in serum and aortae of apolipoprotein E gene knockout mice. J Lipid Res. 2002;43:205-214. (Pubitemid 34184007)
21. Glaros EN, Kim WS, Quinn CM, Jessup W, Rye KA, Garner B. Myriocin slows the progression of established atherosclerotic lesions in apolipoprotein E gene knockout mice. J Lipid Res. 2008;49:324-331. (Pubitemid 351213616)
22. Aerts JM, Ottenhoff R, Powlson AS, Grefhorst A, van Eijk M, Dubbelhuis PF, Aten J, Kuipers F, Serlie MJ, Wennekes T. Pharmacological inhibition of glucosylceramide synthase enhances insulin sensitivity. Diabetes. 2007;56:1341-1349. (Pubitemid 46715620)
23. Bijl N, Sokolović M, Vrins C, Langeveld M, Moerland PD, Ottenhoff R, van Roomen CP, Claessen N, Boot RG, Aten J. Modulation of glycosphingolipid metabolism significantly improves hepatic insulin sensitivity and reverses hepatic steatosis in mice. Hepatology. 2009; 50:1431-1441.
24. McEachern KA, Fung J, Komarnitsky S, Siegel CS, Chuang W-L, Hutto E, Shayman JA, Grabowski GA, Aerts JM, Cheng SH. A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease. Molec Genet Metab. 2007;91:259-267. (Pubitemid 46819125)
25. Chatterjee S. Methods for treatment of angiogenesis. US Patent application #20090202439. Issued August 13, 2009.
26. Chatterjee S, Alsaeedi N, Hou J, Bandaru VV, Wu L, Halushka MK, Pili R, Ndikuyeze G, Haughey NJ. Use of a glycolipid inhibitor to ameliorate renal cancer in a mouse model. PLoS One. 2013;8:e63726.
27. Hyder JA, Allison MA, Barrett-Connor E, Detrano R, Wong ND, Sirlin C, Gapstur SM, Ouyang P, Carr JJ, Criqui MH. Bone mineral density and atherosclerosis: the Multi-Ethnic Study of Atherosclerosis, Abdominal Aortic Calcium Study. Atherosclerosis. 2010;209:283-289.
28. Takahashi S, Suzuki J, Kohno M, Oida K, Tamai T, Miyabo S, Yamamoto T, Nakai T. Enhancement of the binding of triglyceride-rich lipoproteins to the very low density lipoprotein receptor by apolipoprotein E and lipoprotein lipase. J Biol Chem. 1995;270:15747-15754.
29. Chatterjee S, Bhunia AK, Snowden A, Han H. Oxidized low density lipoproteins stimulate galactosyltransferase activity, RAS activation, p44 mitogen activated protein kinase and c-fos expression in aortic smooth muscle cells. Glycobiology. 1997;7:703-710. (Pubitemid 27308498)